CD3-specific antibodies: a portal to the treatment of autoimmunity

@article{Chatenoud2007CD3specificAA,
  title={CD3-specific antibodies: a portal to the treatment of autoimmunity},
  author={Lucienne Chatenoud and Jeffrey A. Bluestone},
  journal={Nature Reviews Immunology},
  year={2007},
  volume={7},
  pages={622-632}
}
Targeted immunotherapies hold great promise for the treatment and cure of autoimmune diseases. The efficacy of CD3-specific monoclonal antibody therapy in mice and humans stems from its ability to re-establish immune homeostasis in treated individuals. This occurs through modulation of the T-cell receptor (TCR)–CD3 complex (also termed antigenic modulation) and/or induction of apoptosis of activated autoreactive T cells, which leaves behind 'space' for homeostatic reconstitution that favours… 
New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
TLDR
Preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed are reviewed and an outlook on future developments to enhance the efficacy of this promising therapeutic approach is provided.
Induction of Immunological Tolerance by Oral Anti-CD3
TLDR
Findings that identify a novel and powerful immunologic approach that is widely applicable for the treatment of human autoimmune conditions are reviewed.
Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity
  • L. Chatenoud
  • Biology, Medicine
    Current opinion in organ transplantation
  • 2009
TLDR
The present challenge is to build on data showing that monoclonal antibodies to the CD3 complex, the signal transducing element of the T cell receptor, promote immune tolerance, and address if and how this therapeutic strategy could be extended to organ transplantation in the not-too-distant future.
Boosting regulatory T cell function by CD4 stimulation enters the clinic
TLDR
This review summarizes the current knowledge on the role of Treg in peripheral tolerance, addresses the putative mechanisms of T Reg-mediated suppression and discusses the clinical potential of harnessing Treg suppressive activity through CD4 stimulation.
The Role of T Cell Tolerance in the Pathogenesis and Treatment of Autoimmune Diseases
TLDR
The basic mechanism of T cell tolerance and theoretical framework of translating these concepts to clinical therapeutics are discussed and the potential applications of these concepts in autoimmune diseases are discussed.
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities
TLDR
The core basic science and animal model studies of Tregs are summarized, the status of multiple biologic and small molecule chemical compounds to promote Treg development in vivo are reviewed, and recent advances for the identification and expansion of polyclonal and antigen‐specific Treg's for adoptive immunotherapy are discussed.
...
...

References

SHOWING 1-10 OF 121 REFERENCES
CD3-specific antibody-induced active tolerance: from bench to bedside
TLDR
CD3-specific antibodies arrest ongoing disease by rapidly clearing pathogenic T cells from the target and promote long-term T-cell-mediated active tolerance, and recent data indicate that transforming growth factor-β-dependent CD4+CD25+ regulatory T cells might have a central role in this effect.
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells
TLDR
It is found that orally administered CD3-specific antibody is biologically active in the gut and suppresses autoimmune encephalomyelitis both before induction of disease and at the height of disease.
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
TLDR
It is strongly suggested that self-tolerance can be restored in adult mice once autoimmunity is fully established and confirmed that this effect can be obtained by transient targeting of the CD3/T-cell receptor without massive T-cell debulking.
Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1
TLDR
Results indicate that nonmitogenic anti-CD3 directly induces a state of immune unresponsiveness in primed pathogenic autoreactive effector cells via mechanisms that may involve the induction of T cell tolerance, apoptosis, and/or alterations in cell trafficking.
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
TLDR
A potential therapeutic use for this novel immunomodulatory approach in an array of T cell-mediated diseases is suggested.
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
TLDR
It is demonstrated that a novel combination treatment with anti-CD3epsilon-specific antibody and i.n. proinsulin peptide can reverse recent-onset diabetes in 2 murine diabetes models with much higher efficacy than with monotherapy with anti -CD3 or antigen alone.
New reagents on the horizon for immune tolerance.
TLDR
Unlocking the key to tolerance induction in the future will likely depend on the ability to harness the functions of T regulatory cells, which are strategically positioned at the interface between innate and adaptive immunity.
The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties
TLDR
The aglycosyl γl CD3 mAb is a promising candidate for immunosuppressive therapy without “first dose” side effects and removal of the carbohydrate moiety from theγl constant region reduced the in vivo tumor necrosis factor‐a response by a factor of at least 16‐fold.
Immune therapies of autoimmune diseases: are we approaching a real cure?
  • L. Chatenoud
  • Biology, Medicine
    Current opinion in immunology
  • 2006
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
TLDR
The present understanding of how classical and new immunosuppressive agents interfere with dendritic cells development and function is reviewed to provide a rational basis for the selection of immunOSuppressive drugs in different clinical settings and for the generation of tolerogenic DCs in the laboratory.
...
...